Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic

References

• Abraham, A. J., Adams, G. B., Bradford, A. C., & Bradford, W. D. (2019). County-level access to opioid use disorder medications in medicare Part D (2010-2015). Health Services Research, 54(2), 390–398. https://doi.org/10.1111/1475-6773.13113
   PubMed Web of Science ®Google Scholar
• Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Archives of Internal Medicine, 171(5), 425–431. https://doi.org/10.1001/archinternmed.2010.541
   PubMedGoogle Scholar
• Andrilla, C. H. A., Moore, T. E., & Patterson, D. G. (2019). Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: Recommendations from rural physicians. The Journal of Rural Health, 35(1), 113–121. https://doi.org/10.1111/jrh.12328
   PubMed Web of Science ®Google Scholar
• Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307
   PubMed Web of Science ®Google Scholar
• Corrigan, P. W., Morris, S. B., Michaels, P. J., Rafacz, J. D., & Rusch, N. (2012). Challenging the public stigma of mental illness: A meta-analysis of outcome studies. Psychiatric Services, 63(10), 963–973. https://doi.org/10.1176/appi.ps.201100529
   PubMed Web of Science ®Google Scholar
• Cunningham, C. O., Sohler, N. L., McCoy, K., & Kunins, H. V. (2006). Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Family Medicine, 38(5), 336–340. http://www.ncbi.nlm.nih.gov/pubmed/16673195
   PubMed Web of Science ®Google Scholar
• DeFlavio, J. R., Rolin, S. A., Nordstrom, B. R., & Kazal, L. A.Jr.(2015). Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural and Remote Health, 15, 3019. http://www.ncbi.nlm.nih.gov/pubmed/25651434https://doi.org/10.22605/RRH3019
   PubMed Web of Science ®Google Scholar
• Dumenco, L., Monteiro, K., Collins, S., Stewart, C., Berkowitz, L., Flanigan, T., Rich, J., & George, P. (2019). A qualitative analysis of interprofessional students’ perceptions toward patients with opioid use disorder after a patient panel experience. Substance Abuse, 40(2), 125–131. https://doi.org/10.1080/08897077.2018.1546262
   PubMed Web of Science ®Google Scholar
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10), 949–958. https://doi.org/10.1056/NEJMoa022164
   PubMed Web of Science ®Google Scholar
• Haffajee, R. L., Bohnert, A. S. B., & Lagisetty, P. A. (2018). Policy pathways to address provider workforce barriers to buprenorphine treatment. American Journal of Preventive Medicine, 54(6), S230–S242. https://doi.org/10.1016/j.amepre.2017.12.022
   PubMed Web of Science ®Google Scholar
• Huhn, A. S., & Dunn, K. E. (2017). Why aren’t physicians prescribing more buprenorphine?Journal of Substance Abuse Treatment, 78, 1–7. https://doi.org/10.1016/j.jsat.2017.04.005
   PubMed Web of Science ®Google Scholar
• Hutchinson, E., Catlin, M., Andrilla, C. H., Baldwin, L. M., & Rosenblatt, R. A. (2014). Barriers to primary care physicians prescribing buprenorphine. The Annals of Family Medicine, 12(2), 128–133. https://doi.org/10.1370/afm.1595
   PubMed Web of Science ®Google Scholar
• James, J. R., Gordon, L. M., Klein, J. W., Merrill, J. O., & Tsui, J. I. (2019). Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. Substance Abuse, 40(1), 11–13. https://doi.org/10.1080/08897077.2018.1449176
   PubMed Web of Science ®Google Scholar
• Kelly, J. F., & Westerhoff, C. M. (2010). Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal on Drug Policy., 21(3), 202–207. https://doi.org/10.1016/j.drugpo.2009.10.010
   PubMed Web of Science ®Google Scholar
• Knudsen, H. K. P., Lin, L. M., & Lofwall, M. M. (2019). Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis. Substance Abuse, 1–10. https://doi.org/10.1080/08897077.2019.1635959
   Google Scholar
• Peckover, S., & Chidlaw, R. G. (2007). Too frightened to care? Accounts by district nurses working with clients who misuse substances. Health & Social Care in the Community, 15(3), 238–245. https://doi.org/10.1111/j.1365-2524.2006.00683.x
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (2013). Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings (NSDUH Series H-46, HHS Publication No. (SMA) 13-4795., Issue. S. A. a. M. H. S. Administration. https://www.samhsa.gov/data/sites/default/files/NSDUHresults2012/NSDUHresults2012.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration (2019). Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf
   Google Scholar
• van Boekel, L. C., Brouwers, E. P. M., van Weeghel, J., & Garretsen, H. F. L. (2014). Healthcare professionals’ regard towards working with patients with substance use disorders: Comparison of primary care, general psychiatry and specialist addiction services. Drug and Alcohol Dependence, 134, 92–98. https://doi.org/10.1016/j.drugalcdep.2013.09.012
   PubMed Web of Science ®Google Scholar
• Wakeman, S. E., & Rich, J. D. (2018). Barriers to Medications for Addiction Treatment: How Stigma Kills. Substance Use & Misuse, 53(2), 330–333. https://doi.org/10.1080/10826084.2017.1363238
   PubMed Web of Science ®Google Scholar
• Walley, A. Y., Alperen, J. K., Cheng, D. M., Botticelli, M., Castro-Donlan, C., Samet, J. H., & Alford, D. P. (2008). Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine, 23(9), 1393–1398. https://doi.org/10.1007/s11606-008-0686-x
   PubMed Web of Science ®Google Scholar
• Wilson, N., Kariisa, M., Seth, P., Smith, H. t., & Davis, N. L. (2020). Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. MMWR. Morbidity and Mortality Weekly Report, 69(11), 290–297. https://doi.org/10.15585/mmwr.mm6911a4
   PubMed Web of Science ®Google Scholar